Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

Summary

The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) clinical drug trials.

Timeline

Start

2007-05

Primary completion

2011-03

Completion

2011-07

Publications

• Patel N, Hegele RA. Mipomersen as a potential adjunctive therapy for hypercholesterolemia. Expert Opin Pharmacother. 2010 Oct;11(15):2569-72. doi: 10.1517/14656566.2010.512006.

Drugs

Indications